StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.31−0.40 (-3.73%)

Close on Nov 18, 2026Market cap $630.32MP/E –Yield –

Janux Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Janux Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$143.56M. For fiscal 2025 it was -$157.67M. The highest annual figure on record is -$4.84M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$157.67M–
FY2024Dec 31, 2024-$98.85M–
FY2023Dec 31, 2023-$72.98M–
FY2022Dec 31, 2022-$67.09M–
FY2021Dec 31, 2021-$32.93M–
FY2020Dec 31, 2020-$4.84M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.69M–
Q1 FY2026Mar 31, 2026-$34.21M–
Q4 FY2025Dec 31, 2025-$42.40M–
Q3 FY2025Sep 30, 2025-$35.25M–
Q2 FY2025Jun 30, 2025-$45.12M–
Q1 FY2025Mar 31, 2025-$34.90M–
Q4 FY2024Dec 31, 2024-$29.02M–
Q3 FY2024Sep 30, 2024-$35.84M–
Q2 FY2024Jun 30, 2024-$13.82M–
Q1 FY2024Mar 31, 2024-$20.16M–
Q4 FY2023Dec 31, 2023-$16.14M–
Q3 FY2023Sep 30, 2023-$15.81M–
Q2 FY2023Jun 30, 2023-$20.75M–
Q1 FY2023Mar 31, 2023-$20.28M–
Q4 FY2022Dec 31, 2022-$18.27M–
Q3 FY2022Sep 30, 2022-$18.02M–
Q2 FY2022Jun 30, 2022-$17.26M–
Q1 FY2022Mar 31, 2022-$13.54M–
Q4 FY2021Dec 31, 2021-$13.49M–
Q3 FY2021Sep 30, 2021-$10.90M–
Q2 FY2021Jun 30, 2021-$6.25M–
Q1 FY2021Mar 31, 2021-$2.28M–
Q4 FY2020Dec 31, 2020-$1.66M–
Q3 FY2020Sep 30, 2020-$1.26M–
Q2 FY2020Jun 30, 2020-$1.11M–

More Janux Therapeutics figures

See a number that looks wrong?